168 related articles for article (PubMed ID: 12627468)
1. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).
Hernandez-Avila CA; Wand G; Luo X; Gelernter J; Kranzler HR
Am J Med Genet B Neuropsychiatr Genet; 2003 Apr; 118B(1):60-5. PubMed ID: 12627468
[TBL] [Abstract][Full Text] [Related]
2. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation.
Hernandez-Avila CA; Covault J; Wand G; Zhang H; Gelernter J; Kranzler HR
Pharmacogenet Genomics; 2007 Dec; 17(12):1031-8. PubMed ID: 18004207
[TBL] [Abstract][Full Text] [Related]
3. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade.
Wand GS; McCaul M; Yang X; Reynolds J; Gotjen D; Lee S; Ali A
Neuropsychopharmacology; 2002 Jan; 26(1):106-14. PubMed ID: 11751037
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
5. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress.
Chong RY; Oswald L; Yang X; Uhart M; Lin PI; Wand GS
Neuropsychopharmacology; 2006 Jan; 31(1):204-11. PubMed ID: 16123758
[TBL] [Abstract][Full Text] [Related]
6. Association study of personality factors and the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1).
Hernandez-Avila CA; Covault J; Gelernter J; Kranzler HR
Psychiatr Genet; 2004 Jun; 14(2):89-92. PubMed ID: 15167694
[TBL] [Abstract][Full Text] [Related]
7. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis.
Arias A; Feinn R; Kranzler HR
Drug Alcohol Depend; 2006 Jul; 83(3):262-8. PubMed ID: 16387451
[TBL] [Abstract][Full Text] [Related]
8. Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism.
Hernandez-Avila CA; Oncken C; Van Kirk J; Wand G; Kranzler HR
Biol Psychiatry; 2002 Apr; 51(8):652-8. PubMed ID: 11955465
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
[TBL] [Abstract][Full Text] [Related]
10. The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.
Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME
Addict Biol; 2013 Jan; 18(1):181-92. PubMed ID: 22264217
[TBL] [Abstract][Full Text] [Related]
11. Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G.
Lovallo WR; Enoch MA; Acheson A; Cohoon AJ; Sorocco KH; Hodgkinson CA; Vincent AS; Glahn DC; Goldman D
Neuropsychopharmacology; 2015 Oct; 40(11):2546-54. PubMed ID: 25881118
[TBL] [Abstract][Full Text] [Related]
12. The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects.
Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME
Alcohol; 2012 Sep; 46(6):511-7. PubMed ID: 22717196
[TBL] [Abstract][Full Text] [Related]
13. Effect of sodium valproate on naloxone-stimulated ACTH and cortisol release in humans.
Torpy DJ; Grice JE; Hockings GI; Crosbie GV; Walters MM; Jackson RV
Clin Exp Pharmacol Physiol; 1995; 22(6-7):441-3. PubMed ID: 8582096
[TBL] [Abstract][Full Text] [Related]
14. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report.
Oswald LM; McCaul M; Choi L; Yang X; Wand GS
Biol Psychiatry; 2004 Jan; 55(1):102-5. PubMed ID: 14706432
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
16. Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene.
Bart G; LaForge KS; Borg L; Lilly C; Ho A; Kreek MJ
Neuropsychopharmacology; 2006 Oct; 31(10):2313-7. PubMed ID: 16794569
[TBL] [Abstract][Full Text] [Related]
17. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
[TBL] [Abstract][Full Text] [Related]
18. Cortisol and adrenocorticotropic hormone responses to naloxone in subjects with high and low neuroticism.
Mangold DL; Wand GS
Biol Psychiatry; 2006 Oct; 60(8):850-5. PubMed ID: 16950229
[TBL] [Abstract][Full Text] [Related]
19. Naloxone decreases the inhibitory effect of alprazolam on the release of adrenocorticotropin/cortisol induced by physical exercise in man.
Coiro V; Volpi R; Casti A; Maffei ML; Stella A; Volta E; Chiodera P
Br J Clin Pharmacol; 2011 Jun; 71(6):951-5. PubMed ID: 21564163
[TBL] [Abstract][Full Text] [Related]
20. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
Lerman C; Wileyto EP; Patterson F; Rukstalis M; Audrain-McGovern J; Restine S; Shields PG; Kaufmann V; Redden D; Benowitz N; Berrettini WH
Pharmacogenomics J; 2004; 4(3):184-92. PubMed ID: 15007373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
